Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging
Ivo H. J. Ploemen, Miguel Prudêncio, Bruno G. Douradinha et al. · 2009
Read Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging by Ivo H. J. Ploemen, Miguel Prudêncio, Bruno G. Douradinha et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007881.txt.
Introduction
Ivo Ploemen and co-authors published a study in PLOS ONE in 2009. It makes the malaria parasite's liver stage visible in real time. After a mosquito bite, Plasmodium parasites first grow inside the liver. That phase is important, yet hard to study.
Infection rates in lab animals and cultured cells are low. The methods to watch parasites develop inside cells were also complicated. The team used real time imaging to visualize and count the rodent malaria liver stage. Clear numbers from this phase can speed vaccine and drug tests. The liver stage is a tempting bottleneck to attack.
Catalog record
| CREATOR | Ivo H. J. Ploemen, Miguel Prudêncio, Bruno G. Douradinha et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007881
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging Authors: Ivo H. J. Ploemen, Miguel Prudêncio, Bruno G. Douradinha, Jai Ramesar, Jannik Fonager, Geert-Jan van Gemert, Adrian J. F. Luty, Cornelus C. Hermsen, Robert W. Sauerwein, Fernanda G. Baptista, Maria M. Mota, Andrew P. Waters, Ivo Que, Clemens W. G. M. Lowik, Shahid M. Khan, Chris J. Janse, Blandine M. D. Franke-Fayard Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0007881 ABSTRACT The quantitative analysis of Plasmodium development in the liver in laboratory animals in cultured cells is hampered by low parasite infection rates and the complicated methods required to monitor intracellular development. As a consequence, this important phase of the parasite's life cycle has been poorly studied compared to blood stages, for example in screening anti-malarial drugs. Here we report the use of a transgenic P. berghei parasite, Pb GFP-Luc con , expressing the bioluminescent reporter protein luciferase to visualize and quantify parasite development in liver cells both in culture and in live mice using real-time luminescence imaging. The reporter-parasite based quantification in cultured hepatocytes by real-time imaging or using a microplate reader correlates very well with established quantitative RT-PCR methods. For the first time the liver stage of Plasmodium is visualized in whole bodies of live mice and we were able to discriminate as few as 1–5 infected hepatocytes per liver in mice using 2D-imaging and to identify individual infected hepatocytes by 3D-imaging. The analysis of liver infections by whole body imaging shows a good correlation with quantitative RT-PCR analysis of extracted livers. The luminescence-based analysis of the effects of various drugs on in vitro hepatocyte infection shows that this method can effectively be used for in vitro screening of compounds targeting Plasmodium liver stages. Furthermore, by analysing the effect of primaquine and tafenoquine in vivo we demonstrate the applicability of real time imaging to assess parasite drug sensitivity in the liver. The simplicity and speed of quantitative analysis of liver-stage development by real-time imaging compared to the PCR methodologies, as well as the possibility to analyse liver development in live mice without surgery, opens up new possibilities for research on Plasmodium liver infections and for validating the effect of drugs and vaccines on the liver stage of Plasmodium . INTRODUCTION Malaria remains a major cause of global morbidity and mortality. New anti-malarial drugs are urgently needed, especially with the increase in drug resistant parasites and the lack of effective vaccines and vector control measures [1] – [4] . The main site for intracellular development of human and rodent Plasmodium sporozoites after they are injected by an infected mosquito is the liver. This stage of the parasite's development is clinically silent and therefore regarded as an ideal point of intervention for prophylactic or vaccine strategies [5] – [7] . The liver stage of Plasmodium 's life cycle has also received particular attention in the context of P. vivax , the second most important agent of human malaria, which can generate cryptic forms called hypnozoites that persist in the liver for long periods of time [8] – [10] . These dormant forms of the parasite are responsible for what is termed relapsing malaria, which may occur following latent periods of months or even years without new infection [10] , [11] . In comparison with drugs that kill blood stage parasites, only a limited number of drugs exist that act on liver stages; most notable amongst these are primaquine, atovaquone and tafenoquine [12] , [13] , and only primaquine [14] , [15] has been shown to act on the hypnozoite stage of P. vivax [14] , [15] . Clearly, the development of new inhibitors/drugs against the malaria liver stage would target an important and under-exploited site of intervention [1] , [16] . Quantitative analysis of liver stage Plasmodium development both in vivo in laboratory rodents and in vitro in cultured liver cells is hampered by the low levels of parasite infection and by the complicated methods required to monitor parasite development. As a consequence, the development of novel and efficient methods for analysing/screening the effect of drugs and small molecule inhibitors on the parasite's intracellular growth in the liver lags well behind the more rapid developments being made in the automated drug/inhibitor screening assays for blood stage parasites [17] – [20] . Currently, one of the standard ways to assess drug efficacy against liver stages is to monitor in vitro liver stage development by quantitative RT-PCR (qRT-PCR) methods [21] – [23] [24] , [25] that are time consuming and expensive. Other studies have involved direct quantification and viability of parasite development by microscopy [26] , [27] , RNA hybridization [28] , or infrared fluorescence scanning system [29] . However, these methods are not only prone to large variations between observers but are also time consuming given the very low infection rates (generally less than 2%) observed in cultured hepatocytes [29] . Moreover, simple and efficient methods for analysing in vivo liver stage development in small laboratory animals are completely absent. The recent generation of new transgenic rodent malaria parasites expressing fluorescent reporter proteins has enabled an intimate analysis of Plasmodium sporozoites interacting with host hepatocytes during invasion and subsequent development inside hepatocytes, both in vitro and in vivo [30] – [34] . Recently, GFP-expressing parasites have been used in conjunction with flow cytometry to provide quantitative information on the parasites development in hepatic cells [35] . However, the use of fluorescent parasites in in vivo analysis of Plasmodium liver stage development requires complex surgery and when such parasites are used in conjunction with flow cytometry, their usefulness is presently restricted to in vitro and ex vivo analyses. We have previously reported the use of transgenic P. berghei parasites expressing the bioluminescent reporter protein, luciferase, to examine the distribution and development of sequestering blood stage parasites in live animals using real time imaging [36] , [37] . Recently, we have also shown the effectiveness of such bioluminescent reporter parasites in simple and sensitive microplate reader assays for screening of drugs against blood stage parasites both in vitro and in vivo in rodents [19] . For these assays we generated a transgenic P. berghei parasite line that expresses a luciferase-GFP fusion protein and is free of a drug-selectable-marker [38] . In the study described here, we utilised the luminescent properties of this reporter parasite, Pb GFP-Luc con , to analyse liver stage development by real time imaging both in cultured hepatocytes and within the liver of living mice. We established that the changes in bioluminescence are directly proportional to the level of hepatocyte infection in vitro and in vivo , determined by comparison with standard qRT-PCR methodologies. As the liver parasite infection progresses real-time in vivo imaging allows the identification of individual infected hepatocytes in living animals. We demonstrated the application of the technique for the in vitro screening of compounds targeting the liver stage and the use of real-time imaging to determine in vivo drug sensitivity of liver stages through analysis of the effect of primaquine. Importantly, bioluminescence imaging also allows the course of an infection to be monitored, both throughout liver stage parasite development and in the blood stage of infection without sacrificing the animal, and therefore, can